Unless you were stuck under an autoclave yesterday, you've heard that another personal genomics company, Knome, announced that it was open for business.
For the bloggers' perspective, you can check out any number of sites. Bertalan Meskó jumps in with a review of Knome's website, scientific advisors, and business model -- and concludes that skepticism reigns "as Knome doesn't say a word about how they can connect the data of whole-genome sequencing to the future of my health."
Over at VentureBeat, David Hamilton has a two-part analysis of Knome, which is essentially charging customers $350,000 to have their genome sequenced. (Sure, it's pricey. But, hey, Christmas is just around the corner.) Hamilton writes, "Don't be surprised to hear critics kvetch about 'celebrity genomics' or knock Knome for catering to the rich and famous once the word gets out." Go here for part 1 and here for part 2.